Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

Benzinga · 2d ago
Jefferies analyst Akash Tewari maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $870 to $930.